Absolute Antibody expands humanised services  

Antibodies

Absolute Antibody has expanded it Prometheus antibody humanisation service to deliver humanised antibodies from a wider range of species than it had previously had.  

The company’s Prometheus antibody humanisation service now offers humanisation from -murine origin species, including rabbit antibodies and single-domain camelid nanobodies. 

Humanisation is a critical step in the development pathway of all therapeutic antibodies derived from non-human sources. Typical humanisation platforms are optimised for humanising mouse or rat antibodies, which are structurally similar to human antibodies.  

However, researchers are looking towards non-murine models, such as rabbits and camelids, as these species offer a range of advantages over more traditional sources of monoclonal antibodies, but structural differences have made humanisation challenging. 

Absolute Antibody’s Prometheus humanisation service has expanded to include rabbit antibodies and single-domain camelid nanobodies. The service delivers a full panel of humanised antibody variants, guaranteeing to produce a variant with comparable activity to the parent clone. It is uniquely focused on enhancing antibody manufacturability, leading to increased expression, lower aggregation, and long-term stability and solubility. 

Official comments 

“Expanding our antibody humanisation service to popular non-murine species enables therapeutics developers to harness the functional and structural advantages of antibodies from non-traditional source organisms,” said Dr Michael Fiebig, Chief Scientific Officer at Absolute Antibody. “Our team specialises in antibody engineering, and we’re always excited to support the innovative scientists working to improve the characteristics of next-generation biotherapeutics.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free